Lyell Immunopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held virtually on June 8, 2022. Lyell Immunopharma, Inc. is a Delaware corporation with its principal executive offices in South San Francisco, California. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 77.79% of outstanding shares (192,242,640 shares) participated in the meeting, establishing a quorum. Two proposals were voted upon:
- Proposal 1: Election of Class I Directors
- Hans Bishop: Elected with 160,815,367 votes for; 2,777,408 votes withheld.
- Catherine Friedman: Elected with 159,405,464 votes for; 4,187,311 votes withheld.
- Robert Nelsen: Elected with 147,699,973 votes for; 15,892,802 votes withheld.
- Proposal 2: Ratification of Auditors
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes For: 192,230,812
- Votes Against: 1,241
- Abstentions: 10,587
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding as of the record date (April 12, 2022) was 247,109,683.
- Note that Robert Nelsen received a significantly higher number of withheld votes (15.9 million) compared to the other two director nominees.
- Confirm the ratification of Ernst & Young LLP for the 2022 fiscal year.
- Review the definitive proxy statement on Schedule 14A filed on April 28, 2022, for detailed background on the proposals.